Thus, IL-6R represents an excellent therapeutic target; IL-6R-blocking mAbs such as tocilizumab and sarilumab have been included in the NIH COVID-19 Treatment Guidelines indicated in hospitalized adults that require oxygen delivery through a high-flow device or noninvasive ventilation [58]. This evidence concerns the gene IL6R and COVID-19.